Key statistics
On Friday, Savara Inc (SVRA:NSQ) closed at 3.36, 19.36% above the 52 week low of 2.82 set on Nov 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.23 |
---|---|
High | 3.44 |
Low | 3.22 |
Bid | 3.30 |
Offer | 3.36 |
Previous close | 3.24 |
Average volume | 2.67m |
---|---|
Shares outstanding | 171.62m |
Free float | 163.76m |
P/E (TTM) | -- |
Market cap | 556.05m USD |
EPS (TTM) | -0.4452 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- Savara Announces New Employment Inducement Grant
- Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
- Savara Announces Participation in Upcoming Healthcare Conferences
- Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
- Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
- Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
- Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
- Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
- Savara to Host Analyst and Investor Webinar on September 30, 2024
More ▼